6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Hypoxia and hypoxia-inducible factors in neuroblastoma

      review-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Hypoxia (i.e., low oxygen levels) is a known feature of aggressive tumors. Cells, including tumor cells, respond to conditions of insufficient oxygen by activating a transcriptional program mainly driven by hypoxia-inducible factors (HIF)-1 and HIF-2. Both HIF-1α and HIF-2α expression levels have been shown to correlate to patient outcome in various tumor forms and in neuroblastoma, a solid childhood tumor of the sympathetic nervous system, in particular, HIF-2α marks a subpopulation of immature neural crest-like perivascularly located cells and associates with aggressive disease and distant metastasis. It has for long been recognized that the HIF-α subunits are oxygen-dependently regulated at the post-translational level, via ubiquitination and proteasomal degradation. Evidence of oxygen-independent mechanisms of regulation, transcriptional control of EPAS1/HIF2A and possible cytoplasmic activities of HIF-2α has also emerged during recent years. In this review, we discuss these non-conventional actions of HIF-2α, its putative role as a therapeutic target and the constraints it carries, as well as the importance of HIF-2 activity in a vascularized setting, the so-called pseudo-hypoxic state.

          Related collections

          Most cited references28

          • Record: found
          • Abstract: found
          • Article: not found

          Hypoxia signalling through mTOR and the unfolded protein response in cancer.

          Hypoxia occurs in the majority of tumours, promoting angiogenesis, metastasis and resistance to therapy. Responses to hypoxia are orchestrated in part through activation of the hypoxia-inducible factor family of transcription factors (HIFs). Recently, two additional O(2)-sensitive signalling pathways have also been implicated: signalling through the mammalian target of rapamycin (mTOR) kinase and signalling through activation of the unfolded protein response (UPR). Although they are activated independently, growing evidence suggests that HIF-, mTOR- and UPR-dependent responses to hypoxia act in an integrated way, influencing each other and common downstream pathways that affect gene expression, metabolism, cell survival, tumorigenesis and tumour growth.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found
            Is Open Access

            Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer.

            Insufficient tissue oxygenation, or hypoxia, contributes to tumor aggressiveness and has a profound impact on clinical outcomes in cancer patients. At decreased oxygen tensions, hypoxia-inducible factors (HIFs) 1 and 2 are stabilized and mediate a hypoxic response, primarily by acting as transcription factors. HIFs exert differential effects on tumor growth and affect important cancer hallmarks including cell proliferation, apoptosis, differentiation, vascularization/angiogenesis, genetic instability, tumor metabolism, tumor immune responses, and invasion and metastasis. As a consequence, HIFs mediate resistance to chemo- and radiotherapy and are associated with poor prognosis in cancer patients. Intriguingly, perivascular tumor cells can also express HIF-2α, thereby forming a "pseudohypoxic" phenotype that further contributes to tumor aggressiveness. Therefore, therapeutic targeting of HIFs in cancer has the potential to improve treatment efficacy. Different strategies to target hypoxic cancer cells and/or HIFs include hypoxia-activated prodrugs and inhibition of HIF dimerization, mRNA or protein expression, DNA binding capacity, and transcriptional activity. Here we review the functions of HIFs in the progression and treatment of malignant solid tumors. We also highlight how HIFs may be targeted to improve the management of patients with therapy-resistant and metastatic cancer.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics.

              Dysregulated signal transduction from receptor tyrosine kinases to phosphatidylinositol 3-kinase (PI3K), AKT (protein kinase B), and its effector FKBP-rapamycin-associated protein (FRAP) occurs via autocrine stimulation or inactivation of the tumor suppressor PTEN in many cancers. Here we demonstrate that in human prostate cancer cells, basal-, growth factor-, and mitogen-induced expression of hypoxia-inducible factor 1 (HIF-1) alpha, the regulated subunit of the transcription factor HIF-1, is blocked by LY294002 and rapamycin, inhibitors of PI3K and FRAP, respectively. HIF-1-dependent gene transcription is blocked by dominant-negative AKT or PI3K and by wild-type PTEN, whereas transcription is stimulated by constitutively active AKT or dominant-negative PTEN. LY294002 and rapamycin also inhibit growth factor- and mitogen-induced secretion of vascular endothelial growth factor, the product of a known HIF-1 target gene, thus linking the PI3K/PTEN/AKT/FRAP pathway, HIF-1, and tumor angiogenesis. These data indicate that pharmacological agents that target PI3K, AKT, or FRAP in tumor cells inhibit HIF-1alpha expression and that such inhibition may contribute to therapeutic efficacy.
                Bookmark

                Author and article information

                Contributors
                Sven.Pahlman@med.lu.se
                Journal
                Cell Tissue Res
                Cell Tissue Res
                Cell and Tissue Research
                Springer Berlin Heidelberg (Berlin/Heidelberg )
                0302-766X
                1432-0878
                14 October 2017
                14 October 2017
                2018
                : 372
                : 2
                : 269-275
                Affiliations
                [1 ]ISNI 0000 0001 0930 2361, GRID grid.4514.4, Translational Cancer Research, Department of Laboratory Medicine, , Lund University, ; Medicon Village, Scheelevägen 8, 223 81 Lund, Sweden
                [2 ]ISNI 0000 0001 0930 2361, GRID grid.4514.4, Pediatric Oncology & Hematology, Department of Clinical Sciences, , Lund University, ; Lund, Sweden
                Article
                2701
                10.1007/s00441-017-2701-1
                5915502
                29032465
                1580eb09-ad14-46ff-96be-9784fc4dddea
                © The Author(s) 2017

                Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

                History
                : 22 June 2017
                : 11 September 2017
                Funding
                Funded by: the SSF Strategic Center for Translational Cancer Research – CREATE Health
                Funded by: VINNOVA
                Funded by: Fru Berta Kamprads stiftelse
                Funded by: BioCARE – a Strategic Research Program at Lund University
                Funded by: Gunnar Nilsson’s Cancer Foundation
                Funded by: the research funds of Malmö University Hospital
                Funded by: the Swedish Research Council
                Funded by: the Swedish Cancer Society
                Funded by: Children’s Cancer Foundation of Sweden
                Categories
                Review
                Custom metadata
                © Springer-Verlag GmbH Germany, part of Springer Nature 2018

                Molecular medicine
                neuroblastoma,hypoxia,hypoxia-inducible factor,vascularization,cancer stem cell
                Molecular medicine
                neuroblastoma, hypoxia, hypoxia-inducible factor, vascularization, cancer stem cell

                Comments

                Comment on this article